All News
Canary in a Coal Mine (4.19.2024)
Dr. Jack Cush reviews regulatory reports, news and novel journal articles - this week focusing on Sjogren's, ILD, Gout and Uveitis.
Read Article
BSR Guideline on Management of Sjogren’s Syndrome
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficient interventions for those affected with mucosal or systemic manifestations.
Read Article
Biopsy Results in Sjogren's Syndrome
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected Sjogren's syndrome (SjD).
Activity & Pain Tolerance (3.29.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com, including where you should sit in clinic and why you should worry about secondary Sjogren's in RA.
Read Article
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity
A Swiss observational study has shown that rheumatoid arthritis (RA) patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
Read Article
#EULAR2024 POS0417 Using EXPLORE Inflammation I & II proteomics, marked immune dysregulation was seen in new ANA+ referral vs HC. 34% progressed to #lupus & #Sjogren. Six potential baseline biomarkers identified & closely resembled established SLE. Validation is ongoing @RheumNow https://t.co/I6HygqNwf7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Nipocalimab (anti-FcRn - i.e. PLEX-in-a-bottle) with a positive phase 2 in Sjogren’s.
This study is in high systemic dx pts (with nice response matching biological plausibility) - but salivary flow improved too
ESSPRI didn’t quite make it, but close #EULAR2024 LBA0010 @RheumNow https://t.co/PslFKJBOOr
Links:
David Liew drdavidliew ( View Tweet)
#EULAR2024 LBA0010 Promising Tx with diff mode of action in antibody+ #Sjogren. Phase 2 RCT Nipocalimab, anti-neonatal Fc receptor (FcRn)Ab that reduces IgG, met primary endpoint (clinESSDAI). Low SIE but doubled in lowest dose vs PBO (unrelated to IgG). On to Phase3 @RheumNow https://t.co/NlCc2l4zFL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 POS1245 Healthcare Administrative Data in Italy showed despite prevalence of 3.8/10,000, heathcare cost in #Sjogren was 3 x higher than the general population due to active disease & comorbidities. Call for better MDT approach in management @RheumNow https://t.co/EevoT4jkqr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#SARD #ILD
Who to screen for #rheumatic #diseases
For
ILD
#ACR guidelines
Screening May also depend on ILD prevalence
Not sure if frequency of screening and how to screen
@jeffsparks #ORA24 @ORAexec https://t.co/BcyyYLKvr6
Links:
Janet Pope Janetbirdope ( View Tweet)
New hypothesis are explored in #Sjogren
#EULAR2024
CB https://t.co/0glF5BGVO5
Links:
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Major pathogenic characteristics of #Sjogren disease
#EULAR2024
CB https://t.co/3NeBBKIVT4
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
Day 1 #EULAR2024 Do you want to learn about the effectiveness of rituximab for systemic features of #Sjogren and potential strategies to overcome non-response? Please come to my talk today (OP0076) and say hi 👋🏼 😃 Room C7 at 1720 hr CET @RheumNow https://t.co/uo2ivC5AeY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
New targets and new treatments in #Sjogren’s disease:
Long term outcomes of repeat cycles of RTX
#EULAR2024
CB https://t.co/6fL3e33i8N
Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
STAR responder may be the way to go! Less placebo effect than CREST.
Better in patients with low systemic activity. https://t.co/mMYOKfG2gS
Links:
Bella Mehta bella_mehta ( View Tweet)
#EULAR2024 OP0008 Phase 2 #Sjogren RCT Iscalimumab, anti-CD40mAb in two cohorts (1=High systemic activity; 2=High symptom burden but low systemic) showed sustained improvement in ESSDAI & ESSPRI at 48wks in ISC-ISC group, as well as those switched at 24wks from PBO-ISC @RheumNow https://t.co/GuifDHA0lK
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#EULAR2024 OP0076 UK multicentre cohort study showed rituximab was effective in systemic features of #Sjogren in children & adults. One in 6 lost response in subsequent cycle due to antidrug antibodies. Humanised or type 2 antiCD20Ab in the future could improve this @RheumNow https://t.co/duYpr2yKGB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
BSR Guideline on Management of Sjogren’s Syndrome
Sjögren disease (SD) is the most common of all autoimmune disease, yet little is know of its etiology and there are insufficent interventions for those affected with mucosal or systemic manifestations.
https://t.co/M5fQ8lyZBS https://t.co/30XpP3r4FV
Dr. John Cush RheumNow ( View Tweet)
Biopsy Results in Sjogren's Syndrome Save
A prospective study from the Netherlands analyzed the comparative value of simultaneous labial and parotid salivary gland biopsies performed in patients with sicca complaints and suspected SjD.
https://t.co/meJgf7dI8N https://t.co/zHg6SgiufS
Dr. John Cush RheumNow ( View Tweet)
Secondary Sjogren’s Ups Rheumatoid Arthritis Severity
A Swiss observational study has shown that RA patients with concomitant Sjögren’s disease (SjD) are more likely to have a severe RA phenotype, and be less responsive to treatment.
https://t.co/4dcackIe4S https://t.co/5VZ9I7r29F
Dr. John Cush RheumNow ( View Tweet)
